Analyst Stock Ratings: Valeant Pharmaceuticals International (NYSE:VRX), Sprint Corp (NYSE:S)

The latest trading activity of 15.74 Million shares is below its average volume of 19.45 Million shares. They now have a $11.00 price objective on the specialty pharmaceutical company’s stock.

On 8/17/2016, shares of Valeant Pharmaceuticals International, Inc.

A number of FactSet analysts shared their views about the current stock momentum.

Once a fervent defender and third-largest investor, T. Rowe Price sold most of its shares in May. Year to date operating cash flow was $14.9 billion and free cash flow was $10.3 billion, both approximately $5.0 billion higher than last year primarily due to improved working capital management, including significant inventory improvement, and timing of payments.

Scrutiny of Valeant’s sharp price increases and of its dealings with pharmacy Philidor RX previous year sent the company’s shares plunging. 1 analysts call it Overweight, while 0 think it is Underweight. Paulson & CO. Inc. now owns 13,265,900 shares of the specialty pharmaceutical company’s stock worth $1,348,479,000 after buying an additional 4,375,900 shares during the last quarter.

The T. Rowe Price lawsuit is separate from pending class-action shareholder litigation in New Jersey that makes similar claims against Valeant and is led by the TIAA pension fund. T. Rowe Price “opted out” of the class action to pursue its claims individually, a move that enables the fund company to pursue certain claims it can’t pursue in a class action. For the current year the company has fixed 9.95B revenues, as per the opinion of 17 analysts.

They lost 3.1 per cent at C$37.30 in afternoon trading on the Toronto Stock Exchange. Six research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The company’s price sits 30.60% above from its 50-day moving average of $23.35 and -45.93% away from the stock’s 200-day moving average which is $38.51. Analyst’s mean target price for SunEdison Semiconductor Limited (NASDAQ:SEMI) is 8.40 while analysts mean recommendation is 2.60.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 1.22, and a price to sales ratio of 0.74. Valeant Pharmaceuticals International, Inc. has its YTD performance of -70.49 Percent. Following the completion of the acquisition, the chief executive officer now directly owns 2,442,199 shares of the company’s stock, valued at $59,785,031.52.